NEW YORK (GenomeWeb News) - Rosetta Genomics will collaborate with Columbia University to develop microRNA-based diagnostic tests for early detection and prognosis of certain types of non-Hodgkin lymphoma and leukemia, Rosetta said today.
Under the collaboration, Rosetta Genomics and Columbia researchers will screen for microRNAs that could serve as biomarkers and drug targets for diffuse large cell lymphoma, transformed follicular lymphoma, and chronic lymphocytic leukemia.
According to Rosetta Genomics Head of Global R&D Dalia Cohen, 40 percent of DLCL patients respond well to current therapies and have prolonged survival, but researchers do not know why the remainder of patients don’t respond to therapy. "We believe our technology will help answer this question, as well as speed up and simplify the diagnostic process,” Cohen said.
The American Cancer Society estimates that around 43,000 people in the US will be diagnosed with these cancers in 2007.